- Home
- KPTI vs PRPL Comparison
KPTI vs PRPL Comparison
Compare KPTI & PRPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- PRPL
- Stock Information
- Founded
- KPTI 2008
- PRPL 2010
- Country
- KPTI United States
- PRPL United States
- Employees
- KPTI N/A
- PRPL N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- PRPL Home Furnishings
- Sector
- KPTI Health Care
- PRPL Consumer Discretionary
- Exchange
- KPTI Nasdaq
- PRPL Nasdaq
- Market Cap
- KPTI 44.5M
- PRPL 96.8M
- IPO Year
- KPTI 2013
- PRPL N/A
- Fundamental
- Price
- KPTI $4.39
- PRPL $0.76
- Analyst Decision
- KPTI Buy
- PRPL Hold
- Analyst Count
- KPTI 6
- PRPL 2
- Target Price
- KPTI $48.50
- PRPL $1.25
- AVG Volume (30 Days)
- KPTI 52.3K
- PRPL 668.3K
- Earning Date
- KPTI 08-05-2025
- PRPL 08-04-2025
- Dividend Yield
- KPTI N/A
- PRPL N/A
- EPS Growth
- KPTI N/A
- PRPL N/A
- EPS
- KPTI N/A
- PRPL N/A
- Revenue
- KPTI $142,126,000.00
- PRPL $472,015,000.00
- Revenue This Year
- KPTI $2.09
- PRPL N/A
- Revenue Next Year
- KPTI $12.90
- PRPL $10.65
- P/E Ratio
- KPTI N/A
- PRPL N/A
- Revenue Growth
- KPTI 1.19
- PRPL N/A
- 52 Week Low
- KPTI $3.51
- PRPL $0.56
- 52 Week High
- KPTI $16.95
- PRPL $1.50
- Technical
- Relative Strength Index (RSI)
- KPTI 45.76
- PRPL 51.44
- Support Level
- KPTI $4.12
- PRPL $0.72
- Resistance Level
- KPTI $4.85
- PRPL $0.79
- Average True Range (ATR)
- KPTI 0.31
- PRPL 0.05
- MACD
- KPTI 0.04
- PRPL 0.00
- Stochastic Oscillator
- KPTI 36.99
- PRPL 53.14
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.